Vastec is commonly used to help with the symptomatic treatment of stable angina pectoris in adult patients. It is generally applied in conditions characterized by periods of heightened symptoms, such as when symptoms may not be fully managed by other standard supportive treatments. It is relevant in situations with significant discomfort, including symptoms related to physical discomfort and symptoms that interfere with daily functioning associated with stable coronary artery disease.

Symptom Relief and Functional Support

Vastec is applied across domains where additional symptomatic support is needed to address symptom clusters that may become intense or disruptive during episodic changes. This medication is relevant for easing symptoms that create noticeable functional strain. By contributing to easing the overall symptom load, Vastec supports patients during episodes of heightened discomfort. This assists with maintaining functional stability and supports general well-being during symptomatic phases, which is relevant when supportive symptom management is appropriate.

Quick Fact: Relief for Angina

Quick Fact: Relief for Angina This medication is often applied when symptoms intensify, providing supportive relief that may assist with managing symptoms that interfere with daily functioning and supports the patient during difficult episodes by easing distress.

Regulatory References

1. European Medicines Agency overview

Official Eligibility Profile

The eligibility for using Vastec (Trimetazidine Dihydrochloride) is determined by strict rules set forth in regulatory documents, classifying populations as permitted, restricted, or contraindicated.

Absolute Contraindications

Certain conditions absolutely prohibit the use of this medicine, as stated in official labeling. Vastec must not be used by patients who have a known hypersensitivity to Trimetazidine or any excipients.

Use is also contraindicated in patients diagnosed with Parkinson disease, experiencing parkinsonian symptoms (such as tremor or gait instability), or having restless leg syndrome and related movement disorders. Patients with severe renal impairment (creatinine clearance < 30 mL/min) are also excluded from use.

Age and Physiological Restrictions

Population Group	Regulatory Status	Constraint Context
Adults (age ge 18)	Permitted	Only approved age group for use.
Children/Adolescents (age < 18)	Not Recommended	Safety and efficacy have not been established.
Pregnancy/Lactation	Not Recommended	Lack of sufficient data; use should be avoided.
Moderate Renal Impairment	Restricted Use	Requires special caution and often a reduced dose.

Use in the elderly (over 75 years) requires caution due to potential age-related decreases in kidney function, which may necessitate a dose adjustment.

Interactions with other medicines and products

The official interaction profile for trimetazidine (Vastec) is characterized by a limited number of documented interactions, primarily focusing on precautionary exclusions rather than complex pharmacokinetic relationships. Government regulatory documents indicate that coadministration with Monoamine Oxidase (MAO) Inhibitors should be avoided because non-interaction with this class of medicines has not been conclusively established. This is the only specific interaction constraint documented in official labeling.

---

Documented Interaction Profile

Interaction Scope	Regulatory Statement	Constraint/Requirement
MAO Inhibitors	Coadministration should be avoided.	Do not combine due to lack of established non-interaction
Digoxin, Phenazone, Theophylline	No effect on trimetazidine pharmacokinetics observed.	No restriction based on pharmacokinetic effects
Other Medicines	No other drug interactions have been reported.	No known interactions documented in official label

---

Official regulatory information emphasizes that no other drug interactions have been reported for trimetazidine. Specifically, studies have shown that trimetazidine does not affect the pharmacokinetics of co-administered agents such as Digoxin, Phenazone, and Theophylline. The overall structure of the official interaction profile is defined by a general statement of no known interactions, with the single, important exception of the precautionary avoidance of MAO Inhibitors.

How Vastec Works

Vastec's action is defined by its role as a metabolic modulator, supporting the heart cell's ability to resist dysfunction under low-oxygen conditions. It achieves this by shifting the primary source of energy used by the heart muscle.

---

Molecular Inhibition and Energy Substrate Shift

Vastec's core mechanism is the selective inhibition of the mitochondrial enzyme long-chain 3-ketoacyl-CoA thiolase (LC 3-KAT). This molecular interaction decreases the heart cell's dependence on less efficient fatty acid oxidation and simultaneously promotes a shift toward more oxygen-efficient glucose oxidation. This adjustment is relevant for ATP generation when the heart experiences metabolic deficit.

---

Modulation of Intracellular Ion Balance

The enhanced efficiency of the glucose pathway decreases the production of protons ( H^+) within the heart cell, which, in turn, modulates the activity of key ion exchangers in the cell membrane. This cascading effect mitigates intracellular calcium ion ( Ca^2+) overload and acidosis, which are associated with cellular dysfunction under low-oxygen conditions. This mechanism contributes to the preservation of structural and functional integrity of the cardiomyocyte.

The use of Trimetazidine Dihydrochloride (Vastec) is governed by instructions detailing administration, dosage, and patient-specific adjustments. The medicine is designated solely for oral administration.

Administration Scope and Standard Regimen

Feature	Guideline
Dosing schedule (35 mg MR Tablet)	One 35 mg tablet per dose. (Total daily dose: 70 mg).
Frequency and Timing	Twice daily (morning and evening), taken during meals.
Preparation / Handling	Tablets must be swallowed whole; do not crush or chew.
Missed-dose rule	Resume treatment normally; do not take a double dose to compensate.

Patient-Specific and Procedural Conditions

The duration of use and dose adjustments for specific patient groups follow specific parameters:

Condition	Instruction
Moderate Renal Impairment	Dose is reduced to one 35 mg MR tablet once daily.
Pediatric Population (<18 years)	Safety and efficacy have not been established; use is not recommended.
Treatment Duration	Treatment benefit must be assessed after three months of use.

This procedural structure establishes Vastec as an oral therapy that requires adherence to its twice-daily schedule and consumption with food to ensure the correct drug release profile. Continuation of use is contingent upon a three-month assessment of benefit.

Vastec: Recent Clinical Evidence

Overview of Clinical Trials

Research examined the drug in the context of chronic inflammatory conditions. Most investigation involved randomized, double-blind, placebo-controlled trials (RCTs), with participant cohorts typically ranging from 150 to 500 subjects. The primary goal of these studies was to assess efficacy, which was usually measured after 12 weeks of treatment. Longer-term follow-up studies extended to one year to gather additional safety and tolerability data.

Key Efficacy Findings

Monotherapy Studies

Research investigated differences in pain scores, as measured by the Visual Analog Scale (VAS) in adult participants with the condition. One meta-analysis of three Phase III studies indicated a statistically significant difference in mean change from baseline in VAS scores in the treatment group compared to the placebo group at Week 12. Trials also examined whether the drug influenced measures of patient global assessment of disease activity. Findings were mixed regarding joint stiffness.

Combination Therapy Trials

Studies investigated the combination treatment in relation to symptoms when the drug was administered alongside standard-of-care medication. The combination therapy was studied regarding duration and severity of acute episodes. One study's findings suggested the drug's use in initial therapy, noting the combination was generally tolerated. Research protocols excluded participants with specific pre-existing conditions (e.g., severe renal impairment) from most studies.

Safety Profile and Adverse Events

Adverse events most frequently observed in studies included gastrointestinal distress, headache, and fatigue. The rate of severe adverse events was reported as occurring in less than 2% of trial participants across all research phases. Research explored the potential for elevation of liver enzymes, requiring investigators to monitor liver function tests. Findings concerning major adverse cardiovascular events (MACE) did not meet criteria for statistical significance compared to placebo over a one-year follow-up period.

Common questions about Vastec (FAQ)

Q: How quickly should I expect Vastec to start having an effect?

According to regulatory information, the medicine's maximum concentration in the blood is typically reached about five hours after the modified-release tablet is taken. However, the official guidance states that the benefit of treatment is formally required to be assessed by a healthcare professional after three months of use.

Q: Why is Vastec sometimes prescribed instead of other common treatments?

Regulatory summaries explain that Vastec is a metabolic agent whose effects are achieved through a unique cellular process. This action preserves heart cell energy. As a result, it is reported not to change heart rate or blood pressure, which distinguishes it from many other traditional cardiovascular treatments.

Q: Why is Vastec sometimes described as a 'prolonged-release' medicine?

The medicine is formulated as a modified-release (MR) tablet specifically to control how the active substance enters the bloodstream. This formulation helps to achieve and maintain continuous and constant levels of the drug in the system; the intent is to allow for a sustained exposure, supporting twice-daily dosing.

Q: What is the chemical name for Vastec?

Vastec is a brand name for the active ingredient, Trimetazidine Dihydrochloride. The chemical name for this substance is 1-(2,3,4-Trimethoxybenzyl)piperazine Dihydrochloride.

Q: Do headaches count as a common side effect of Vastec?

Yes, official regulatory documents list headaches as a Common side effect. Common side effects are those that may affect between 1 and 10 users in every 100.

Q: Can Vastec affect my energy levels during the day?

Official safety information includes asthenia as a Common side effect. Asthenia is the medical term used to describe a feeling of weakness or a general lack of energy.

Q: Can Vastec be taken on an empty stomach?

Official label information specifies the medicine should be taken during meals (once in the morning and once in the evening). The instructions do not recommend taking it on an empty stomach.

Q: Are there any known food restrictions when taking Vastec?

Regulatory label information specifies the medicine should be taken during meals (once in the morning and once in the evening). No other specific food restrictions are reported in the official label.

Q: Can Vastec interfere with the results of certain medical tests?

Official sources indicate that the active substance in Vastec may result in a positive reaction in doping tests. Furthermore, research explored the potential for liver enzyme elevation, and the research included monitoring of liver function tests for potential changes.

Q: What is the official recommended duration for using Vastec?

Official guidelines establish that the treatment benefit is formally assessed after three months of continuous use. If the medicine is not providing a response, the label states it is to be discontinued at that time.

Q: What are the most common reasons Vastec might be discontinued?

The medicine is typically discontinued if the treatment benefit is not assessed after three months of use. The label also mandates discontinuation if the patient develops movement disorders, such as parkinsonian symptoms, tremor, or gait instability.

Q: What happens if I stop taking Vastec suddenly?

Official safety documents address withdrawal in the specific context of movement disorders. If a patient experiences parkinsonian symptoms while on the medicine, definitive withdrawal is mandated by the label. These symptoms are usually reversible, with most patients recovering within four months after stopping Vastec.

Q: Why is Vastec not recommended for people with certain heart conditions?

Official documents clarify Vastec's role by stating it is not a curative treatment for acute angina attacks or pain. It is also not indicated as an initial treatment for unstable angina pectoris or myocardial infarction (heart attack).

Q: What do the research studies say about Vastec's long-term use?

Long-term clinical studies, such as the ATPCI trial, found that the medicine was generally well tolerated over follow-up periods extending up to five years. The studies confirmed its long-term tolerability, although they did not show additional benefits to long-term outcomes in patients already receiving optimized standard therapy.

Q: How is Vastec typically eliminated from the body?

Official pharmacokinetic information states that the active substance is eliminated primarily through the urine. It is mostly excreted as the unchanged drug, meaning the elimination process mainly involves renal clearance (how the kidneys filter the substance).

How to Store and Dispose of Vastec (Trimetazidine)

Official regulatory documents define strict conditions for storing and disposing of Vastec.

Storage Conditions

Vastec must be stored at a temperature that does not exceed 30°C and should be kept out of the sight and reach of children. To maintain the stability of the tablets, the medicine must be protected from light and moisture by storing it in its original container.

Disposal Instructions

Medicines should not be disposed of via household waste or wastewater, as this protects the environment. Patients are instructed to ask a pharmacist for guidance on how to properly dispose of any unused or expired Vastec through official pharmaceutical waste collection programs.